Australia | English

Dexcom CGM

Why Recommend Dexcom CGM for your patients?!

patient and doctor dexcom cgm

Dexcom CGM use lowers HbA1c1,2

Both the DIAMOND study and COMISAIR study showed that Dexcom CGM use can help to reduce HbA1c.1,2 Beck et al (2017) and Soupal et al. (2016) also found that Dexcom CGM use led to more time spent within target glucose range.1,2

 

Dexcom CGM helps to reduce the risk of hypoglycaemia3,4

Heinemann et al. (2018) and Reddy et al. (2018) reported that CGM was an effective tool in minimising the risk of hypoglycaemia.3,4 Specifically, Reddy et al. (2018)  concluded that “CGM more effectively reduces time spent in hypoglycaemia in people with Type 1 diabetes and impaired awareness of hypoglycaemia compared with flash glucose monitoring.”

 

Dexcom CGM use improves quality of life and wellbeing5

Lind et al (2017) demonstrated “a significant improvement in subjective well-being and treatment satisfaction in adults using CGM in comparison with conventional therapy.” 5 Additionally, this study also showed a reduction in hypoglycaemia fear when using CGM.5

 

Dexcom G6 provides exceptional accuracy6

Wadwa et al (2018) concluded that Dexcom G6’s factory-calibrated sensor was able to provide accurate readings throughout the life of the sensor (10 days).6

Clinic Resources

For more useful resources and educational materials, please refer to our MyInteract portal at button below. 

In this portal, you can find:

  • Order forms
  • Training Materials: including set-up checklists, Professional Use booklets and more
  • Webinars and Presentations

ACCESS MYINTERACT

1. Beck RW, Riddlesworth T, Ruedy K, Ahmann A, Bergenstal R, Haller S, Kollman C, Kruger D, McGill JB, Polonsky W, Toschi E, Wolpert H, Price D; DIAMOND Study Group. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial. JAMA. 2017 Jan 24;317(4):371-378. doi: 10.1001/jama.2016.19975. PMID: 28118453

2. Šoupal J, Petruželková L, Flekač M, Pelcl T, Matoulek M, Daňková M, Škrha J, Svačina Š, Prázný M. Comparison of Different Treatment Modalities for Type 1 Diabetes, Including Sensor-Augmented Insulin Regimens, in 52 Weeks of Follow-Up: A COMISAIR Study. Diabetes Technol Ther. 2016 Sep;18(9):532-8. doi: 10.1089/dia.2016.0171. Epub 2016 Aug 2. PMID: 27482825; PMCID: PMC5035377

3. Heinemann L, Freckmann G, Ehrmann D, Faber-Heinemann G, Guerra S, Waldenmaier D & Hermanns N. Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial. The Lancet. 2018;391(10128):1367-1377

4. Reddy M, Jugnee N, El Laboudi A, Spanudakis E, Anantharaja S, Oliver N. A randomized controlled pilot study of continuous glucose monitoring and flash glucose monitoring in people with Type 1 diabetes and impaired awareness of hypoglycaemia. Diabet Med. 2018 Apr;35(4):483-490. doi: 10.1111/dme.13561. Epub 2017 Dec 29. PMID: 29230878; PMCID: PMC5888121

5. Lind M, Polonsky W, Hirsch IB, et al. Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections: The GOLD Randomized Clinical Trial. JAMA. 2017;317(4):379–387. doi:10.1001/jama.2016.19976

6. Wadwa RP, Laffel LM, Shah VN & Garg SK. Accuracy of a Factory-Calibrated, Real-Time Continuous Glucose Monitoring System During 10 Days of Use in Youth and Adults with Diabetes. Diabetes Technol Ther. 2018;20(6):395-402